Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
TPST Stock Chart & Stats
$2.23
$0.02(2.27%)
At close: 4:00 PM EST
$2.23
$0.02(2.27%)
Day’s Range― - ―
52-Week Range$2.17 - $12.48
Previous CloseN/A
Volume2.28M
Average Volume (3M)50.79K
Market Cap
$11.73M
Enterprise Value$11.88M
Total Cash (Recent Filing)$7.51M
Total Debt (Recent Filing)$8.40M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Apr 01, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding4,927,161
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)15.83
Price to Sales (P/S)0.00
P/FCF Ratio-9.05
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-89.31
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$11.00Price Target Upside393.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayTransaction extends the company's cash runway, allowing advancement of the new lead program through initial clinical milestones without immediate additional financing.
Clinical DataAcquisition adds a clinically de‑risked dual‑target CAR‑T, TPST-2003, which produced positive early clinical results and increases the likelihood of achieving pivotal development milestones.
LeadershipDeal installed experienced leadership from the acquired company as CEO, strengthening operational capability and potentially accelerating development execution.
Bears Say
Legacy Program DeprioritizationLegacy oncology programs such as amezalpat and TPST-1495 are deprioritized and will need new financing or partnerships to progress, increasing the risk those assets stall.
Pipeline Concentration RiskStrategic pivot concentrates development risk on the newly acquired cell therapy, increasing exposure if that lead program encounters clinical or regulatory setbacks.
Shareholder DilutionExisting shareholders lose majority ownership in the combined company and face substantial dilution from the transaction structure, which could weigh on shareholder value.
Tempest Therapeutics News
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $2.17 and its highest was $12.48 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $11.73M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 53 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$3.27 by $2.48.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.62.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 4,927,161 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$3.27. Following the earnings report the stock price went up 9.101%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
TPST Stock 12 Month Forecast
Average Price Target
$11.00
▲(393.27% Upside)
Technical Analysis
Ownership Overview
―
Insiders
3.43% Mutual Funds
1.00% Other Institutional Investors
92.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---